Neuro & Sleep.
The neuro bench: DSIP, selank, semax in two strengths, and melatonin. A good deal of the clinical work behind this group was published in Russian and never translated, which is a real limit on what anyone can tell you about it — including us.
Worth reading first
Claims we checkedDSIP: the one controlled human trial ended in a negative result
Sixteen chronic insomniacs received 25 nmol/kg of DSIP intravenously in a double-blind matched-pairs design across three nights, and the authors concluded it is not likely to be of major therapeutic benefit because the significant effects were weak. The recent pharmacology is mice. This page reports both.
Claims we checkedSelank: three small clinical studies, one fMRI crossover
A heptapeptide analogue of tuftsin, sold for anxiety, with 62, 60 and 70-patient studies published in one Russian journal and one 52-participant fMRI crossover in healthy volunteers. The controlled trials do not use placebo, do not report blinding, and do not print an amount in the abstract. This page counts what exists rather than asserting what it means.
RepairDSIP: the peptide named for sleep, and what it was measured doing
Isolated from rabbit blood in 1977 and named for slow-wave sleep, DSIP reduced slow-wave sleep in cats when it was actually tested. The sleep hypothesis has been described in the peer-reviewed literature as extremely poorly documented and still weak.